Corteva, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CTVA in the last 30 days.
See all $CTVA insider activity →A federal judge denied Inari Agriculture's request to reduce claims in Corteva's patent infringement suit, which is set for trial. Corteva argues Inari is liable for testing its corn seeds, despite Inari's claim that the tests were conducted by Iowa State University. The judge ruled in Corteva's favor.
Corteva's Vylor division announced a corn technology pipeline through 2035, aiming to improve yield and stability. Field trials showed average gains of 3 bushels per acre, with up to 10. The portfolio is expected to generate over $2 billion in incremental revenue by 2035, with seven new platforms launching across 90% of Vylor's corn business. Key technologies include disease-resistant and insect-control traits.
Inari was denied judgments of noninfringement on most US patent claims brought by Corteva regarding corn and soybean crops. District Judge John F. Murphy allowed only five of Corteva's claims to be dismissed.
Over the past 7 days, alphai's AI scored 3 news stories mentioning CTVA (Corteva, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent CTVA coverage spans regulation, corporate actions and technology.
The ruling maintains legal exposure for Corteva, potentially pressuring the stock.
Long‑term revenue boost from new corn traits could improve Corteva's growth outlook.
Inari was denied judgments of noninfringement on most US patent claims brought by Corteva regarding corn and soybean crops. District Judge John F. Murphy allowed only five of Corteva's claims to be dismissed.
The spin‑off creates a pure‑play genetics company, potentially unlocking valuation multiple for both entities.
The settlement highlights regulatory risk for Corteva and may pressure its stock.
alphai scores every news story that mentions CTVA with an AI model for sentiment and relevance, and aggregates insider trades from Corteva, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
A federal judge denied Inari Agriculture's request to reduce claims in Corteva's patent infringement suit, which is set for trial. Corteva argues Inari is liable for testing its corn seeds, despite Inari's claim that the tests were conducted by Iowa State University. The judge ruled in Corteva's favor.
1 min readCorteva's Vylor division announced a corn technology pipeline through 2035, aiming to improve yield and stability. Field trials showed average gains of 3 bushels per acre, with up to 10. The portfolio is expected to generate over $2 billion in incremental revenue by 2035, with seven new platforms launching across 90% of Vylor's corn business. Key technologies include disease-resistant and insect-control traits.
2 min readInari was denied judgments of noninfringement on most US patent claims brought by Corteva regarding corn and soybean crops. District Judge John F. Murphy allowed only five of Corteva's claims to be dismissed.
3 min readCorteva plans to spin off its advanced seed and genetics business, Vylor, by October 1, 2026. The company presented a corn innovation roadmap, highlighting proprietary biotechnology and gene editing technologies expected to generate over $2bn in incremental revenue by 2035, including licensing income. Vylor aims to transition to a technology licensor, creating recurring revenue streams from proprietary genetics and traits.
2 min readCorteva, Inc. agreed to pay $3.1 million to settle an antitrust lawsuit by the Arkansas AG, who alleged that its rebate and loyalty programs suppressed competition. The case is part of broader scrutiny of such programs by state AGs and the FTC. Corteva and Syngenta faced similar allegations, with a judge rejecting their dismissal attempts in 2025. The settlement highlights risks for companies using distributor incentives.
3 min readRBC Capital reiterated an Outperform rating and $103 price target for Corteva (CTVA) ahead of its Vylor spin-off. The firm sees the stock's weakness as an entry point, with a 13x 2027 EBITDA multiple. Corteva's market cap is $55.3B, and it trades at 13.6x EV/EBITDA. RBC maintained FY2026 and FY2027 EBITDA estimates at $4.2B and $4.5B, respectively. UBS and BMO also adjusted their price targets, with UBS citing growth outlook and BMO highlighting EBITDA expectations.
2 min readAgriculture sector shows recovery with fertilizer stocks leading. CF Industries up 62.7% YTD, Nutrien up 19.2%. Wolfe Research notes shift to cautious optimism. Fall fertilizer season and commodity price recovery are key catalysts. CF Industries trades at 9.1x P/E with 20.0% revenue growth. Risks include trade policy and macro slowdown.
3 min readA federal judge ruled that Corteva's seed patents remain valid, rejecting Inari Agriculture's claim that field trials invalidated them. Corteva's patents were challenged due to alleged public display before patent filing. The case will proceed to trial in Delaware next month.
2 min readA US district judge ruled in favor of Corteva in a patent dispute, dismissing Inari's counterclaims. The judge found Inari did not provide sufficient evidence to challenge the validity of Corteva's patents.
1 min readCorteva, Inc. (CTVA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. In connection with the previously announced separation of Corteva, Inc. (the “Company” or “Corteva”) into two independent, publicly traded companies, one comprising its current crop protection business and the other comprising
1 min read
